Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
RNA-binding proteins in human genetic disease
Gebauer, F., Schwarzl, T., Valcárcel, J., & Hentze, M. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00302-y · Cited by 1,176
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124
Molecular mechanisms of cancer development in obesity
Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3174 · Cited by 907
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Self-citationRoberts, A. E., Allanson, J. E., Tartaglia, M., & Gelb, B. D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61023-x · Cited by 793
De Luca, A., Maiello, M. R., D'Alessio, A., Pergameno, M., & Normanno, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.639361 · Cited by 735
RNA-binding proteins in human genetic disease
Lukong, K. E., Chang, K.-W., Khandjian, E. W., & Richard, S. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.05.004 · Cited by 646
“For example, epidermal growth factor receptor 2 (HER2) gene amplification is frequently observed in breast cancer [64], and activating mutations in the RAS oncogene are highly prevalent in colon cancer [ 65 ].”
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
“Constitutive activation of this pathway as a result of mutations is considered a key event in the development of several human malignancies and developmental disorder”
BackgroundBernardi, P., Rasola, A., Forte, M., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 577
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Boutros, T., Chevet, E., & Metrakos, P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00106 · Cited by 545
Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 538
Demory Beckler, M., Higginbotham, J. N., Franklin, J. L., Ham, A.-J., Halvey, P. J., Imasuen, I. E., Whitwell, C., Li, M., Liebler, D. C., & Coffey, R. J. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.022806 · Cited by 524
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
Germline gain-of-function mutations in RAF1 cause Noonan syndrome
Razzaque, M. A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., Kamisago, M., Momma, K., Katayama, H., Nakagawa, M., et al. (2007) · Nature Genetics · doi:10.1038/ng2078 · Cited by 498
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias
for The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project, Andersson, A. K., Ma, J., Wang, J., Chen, X., Gedman, A. L., Dang, J., Nakitandwe, J., Holmfeldt, L., Parker, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3230 · Cited by 490
Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A., Beck, A. H., & Sabatini, D. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 450
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
Pancreatic cancer biology and genetics from an evolutionary perspective
Makohon-Moore, A., & Iacobuzio-Donahue, C. A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.66 · Cited by 431
Cordeddu, V., Di Schiavi, E., Pennacchio, L. A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. (2009) · Nature Genetics · doi:10.1038/ng.425 · Cited by 419
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
Jongen-Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. M., & Löwenberg, B. (2008) · Blood · doi:10.1182/blood-2008-01-133355 · Cited by 403
Clinical Relevance of KRAS in Human Cancers
Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/150960 · Cited by 402
Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A.-E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010130 · Cited by 398
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk
Clayton, P. E., Banerjee, I., Murray, P. G., & Renehan, A. G. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.171 · Cited by 364
“For example, in both Costello syndrome and cardiofaciocutaneous syndromes, RAS and RAF mutations are associated with thyroid, colorectal and ovarian tumors”
BackgroundOncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Dual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Gain-of-Function Mutations in RIT1 Cause Noonan Syndrome, a RAS/MAPK Pathway Syndrome
Aoki, Y., Niihori, T., Banjo, T., Okamoto, N., Mizuno, S., Kurosawa, K., Ogata, T., Takada, F., Yano, M., Ando, T., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.05.021 · Cited by 330
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
A Novel Role for Copper in Ras/Mitogen-Activated Protein Kinase Signaling
Turski, M. L., Brady, D. C., Kim, H. J., Kim, B.-E., Nose, Y., Counter, C. M., Winge, D. R., & Thiele, D. J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05722-11 · Cited by 320
A restricted spectrum of NRAS mutations causes Noonan syndrome
Cirstea, I. C., Kutsche, K., Dvorsky, R., Gremer, L., Carta, C., Horn, D., Roberts, A. E., Lepri, F., Merbitz-Zahradnik, T., König, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.497 · Cited by 315
Souglakos, J., Philips, J., Wang, R., Marwah, S., Silver, M., Tzardi, M., Silver, J., Ogino, S., Hooshmand, S., Kwak, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605164 · Cited by 310
Li, J., Zhang, N., Song, L.-B., Liao, W.-T., Jiang, L.-L., Gong, L.-Y., Wu, J., Yuan, J., Zhang, H.-Z., Zeng, M.-S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4054 · Cited by 307
Sarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M. C., Pantaleoni, F., Scioletti, A. P., Esposito, G., Cordeddu, V., Lepri, F., et al. (2009) · Human Mutation · doi:10.1002/humu.20955 · Cited by 303
Inman, G. J., Wang, J., Nagano, A., Alexandrov, L. B., Purdie, K. J., Taylor, R. G., Sherwood, V., Thomson, J., Hogan, S., Spender, L. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06027-1 · Cited by 297
Mitochondrial gateways to cancer
Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.08.002 · Cited by 300
Labi, V, & Erlacher, M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.20 · Cited by 295
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0103 · Cited by 294
Rho GTPases: functions and association with cancer
Ellenbroek, S. I. J., & Collard, J. G. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9119-1 · Cited by 289
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290
Autophagy-Dependent Production of Secreted Factors Facilitates Oncogenic RAS-Driven Invasion
Lock, R., Kenific, C. M., Leidal, A. M., Salas, E., & Debnath, J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0841 · Cited by 281
Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics
Gawad, C., Koh, W., & Quake, S. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420822111 · Cited by 281
Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1215 · Cited by 280
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 278
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Nan, X., Tamgüney, T. M., Collisson, E. A., Lin, L.-J., Pitt, C., Galeas, J., Lewis, S., Gray, J. W., McCormick, F., & Chu, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509123112 · Cited by 273
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Functional Specificity of Ras Isoforms: So Similar but So Different
Castellano, E., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408081 · Cited by 273
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.06.015 · Cited by 259
Haling, J. R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W., Phung, W., Bravo, B. J., Giannetti, A. M., Peck, A., Masselot, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.007 · Cited by 252
Satoh, H., Moriguchi, T., Takai, J., Ebina, M., & Yamamoto, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4499 · Cited by 251
Histone H3 phosphorylation – A versatile chromatin modification for different occasions
Sawicka, A., & Seiser, C. (2012) · Biochimie · doi:10.1016/j.biochi.2012.04.018 · Cited by 248
Autophagy regulation and its role in cancer
Lorin, S., Hamaï, A., Mehrpour, M., & Codogno, P. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.007 · Cited by 245
Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis
Tartaglia, M., Zampino, G., & Gelb, B. D. (2010) · Molecular Syndromology · doi:10.1159/000276766 · Cited by 246
The biology of IQGAP proteins: beyond the cytoskeleton
Hedman, A. C., Smith, J. M., & Sacks, D. B. (2015) · EMBO reports · doi:10.15252/embr.201439834 · Cited by 245
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Jiang, B.-H., & Liu, L.-Z. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.03.001 · Cited by 243
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
Cdc42 in oncogenic transformation, invasion, and tumorigenesis
Stengel, K., & Zheng, Y. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.04.001 · Cited by 239
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
Precision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Ritt, D. A., Monson, D. M., Specht, S. I., & Morrison, D. K. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00569-09 · Cited by 238
Ho, C., Wang, C., Mattu, S., Destefanis, G., Ladu, S., Delogu, S., Armbruster, J., Fan, L., Lee, S. A., Jiang, L., et al. (2012) · Hepatology · doi:10.1002/hep.24736 · Cited by 233
Posch, C., Moslehi, H., Feeney, L., Green, G. A., Ebaee, A., Feichtenschlager, V., Chong, K., Peng, L., Dimon, M. T., Phillips, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216013110 · Cited by 234
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Buday, L., & Downward, J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.001 · Cited by 230
Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L., Barr, F. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2056 · Cited by 232
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 227
Mate and fuse: how yeast cells do it
Merlini, L., Dudin, O., & Martin, S. G. (2013) · Open Biology · doi:10.1098/rsob.130008 · Cited by 227
Involvement of Autophagy in Oncogenic K-Ras-induced Malignant Cell Transformation
Kim, M.-J., Woo, S.-J., Yoon, C.-H., Lee, J.-S., An, S., Choi, Y.-H., Hwang, S.-G., Yoon, G., & Lee, S.-J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.138958 · Cited by 227
Rasola, A., Sciacovelli, M., Chiara, F., Pantic, B., Brusilow, W. S., & Bernardi, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912742107 · Cited by 225
Suda, K., Tomizawa, K., & Mitsudomi, T. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9209-4 · Cited by 222
Post-translational myristoylation: Fat matters in cellular life and death
Martin, D. D. O., Beauchamp, E., & Berthiaume, L. G. (2011) · Biochimie · doi:10.1016/j.biochi.2010.10.018 · Cited by 223
“This syndrome is a rare developmental disorder resulting in reduced growth, facial dysmorphism, cognitive deficits and malignancies [104,105].”
BackgroundCancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes
Kratz, C. P., Rapisuwon, S., Reed, H., Hasle, H., & Rosenberg, P. S. (2011) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30300 · Cited by 223
Autophagy and cancer – issues we need to digest
Liu, E. Y., & Ryan, K. M. (2012) · Journal of Cell Science · doi:10.1242/jcs.093708 · Cited by 219
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
Kratz, C. P., Franke, L., Peters, H., Kohlschmidt, N., Kazmierczak, B., Finckh, U., Bier, A., Eichhorn, B., Blank, C., Kraus, C., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.75 · Cited by 217
ERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment
Dias Carvalho, P., Guimarães, C. F., Cardoso, A. P., Mendonça, S., Costa, Â. M., Oliveira, M. J., & Velho, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2084 · Cited by 202
Merkel Cell Carcinoma: More Deaths but Still No Pathway to Blame
Lemos, B., & Nghiem, P. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700925 · Cited by 213
Targeting oncogenic Ras signaling in hematologic malignancies
Ward, A. F., Braun, B. S., & Shannon, K. M. (2012) · Blood · doi:10.1182/blood-2012-05-378596 · Cited by 209
Self-citationGoriely, A., Hansen, R. M. S., Taylor, I. B., Olesen, I. A., Jacobsen, G. K., McGowan, S. J., Pfeifer, S. P., McVean, G. A. T., Meyts, E. R.-D., & Wilkie, A. O. M. (2009) · Nature Genetics · doi:10.1038/ng.470 · Cited by 205
Chapter 1 Ras Signaling and Therapies
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02001-6 · Cited by 205
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.